Martin, A., Koenig, K., Anderson, G.M. and Scahill, L. (2003) Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study. Journal of Autism and Developmental Disorders, 33, 77-85.
http://dx.doi.org/10.1023/A:1022234605695

has been cited by the following article:

• TITLE: Milnacipran for Attention-Deficit Hyperactivity Disorder Symptoms in Adult Asperger’s Disorder

  AUTHORS: Hirobumi Mashiko, Hiromichi Ishikawa, Shuntaro Itagaki, Yasuko Takanashi, Norihiro Miyashita, Takaaki Okano, Shin-Ichi Niwa, Hirooki Yabe

  KEYWORDS: Milnacipran, ADHD, Asperger’s Disorder

  JOURNAL NAME: Open Journal of Psychiatry, Vol.4 No.3, July 9, 2014

  ABSTRACT: The efficacy of milnacipran for the treatment of ADHD symptoms in adult Asperger’s disorder patients was examined. Fifteen consecutive adult Asperger’s disorder patients with ADHD symptoms were treated with milnacipran for 8 weeks. Global Assessment of Functioning (GAF) and Conners’ Adult ADHD Rating Scales Objective Screening Version (CAARS-O-SV) were used for the assessment. The mean GAF scores in the 15 patients improved significantly. Inattention, inattention + hyperactivity/impulsivity and ADHD index in CAARS-O-SV were also significantly improved. Milnacipran might be useful for ADHD symptoms, exerting its effects by increasing serotonin and noradrenaline activities in Asperger’s disorder.